A Thousandfold Boost in Glass Knowledge Helps Pharma Industry to Better Package Drugs
News Mar 25, 2015
SCHOTT has reached the landmark of training more than 3,000 professionals at its FIOLAX Academy. Started in 2010, FIOLAX Academy events share the latest information on the composition, properties and production of high quality pharma glass. This knowledge helps the industry to manufacture and use even better vials, syringes, ampoules, and cartridges for the optimal storage of medicines – supporting pharma companies in their efforts to minimize risks and ensure patient safety.
Participants have come from within specialist companies that are converting glass tubes to primary glass packaging, and from pharmaceutical businesses. The academy takes its name from SCHOTT FIOLAX® glass tubing, which has grown to become the gold standard ‘raw material’ for glass containers in the pharma industry. SCHOTT hosts FIOLAX Academy events in many of the world’s leading and emerging pharmaceutical markets.
Since 2010 there have been more than 150 FIOLAX Academies in countries throughout the world, from Europe and US to South and Central America, India, Japan, and China. Dr. Bettine Boltres, Product Manager Pharmaceutical Tubing and responsible for this training program, explains, “At SCHOTT we are thrilled to have already trained so many people in the FIOLAX Academy. We are continually expanding the programme to offer a complete training experience, covering topics such as drug-container interactions, regulatory requirements and glass quality. Through these training events we help our partners to improve quality and to increase efficiency and in turn advance their position in both their domestic and international markets.”
The FIOLAX Academy modular training programme has been designed in six parts. SCHOTT experts share the latest industry information on the use of glass in pharmaceutical ampoule, vial, cartridge and syringe manufacturing. Specialist insight is also provided for drug makers and contract fillers about the handling of glass during the filling processes to help decrease the risk of breakages.
An FDA-approved drug has been identified that, when used with surgery, hampers metastasis in an animal model. Originally developed and approved ~65 years ago to control blood pressure, the medication resperine also prevents what are known as tumor-derived extracellular vesicles from fusing to healthy cells and sharing their cargo of disease-promoting molecules.READ MORE
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019